A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma.
Latest Information Update: 18 Jul 2023
At a glance
- Drugs SB 743921 (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cytokinetics
- 16 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Dec 2009 Results presented at ASH 2009, according to a Cytokinetics media release.
- 01 Dec 2009 According to a Cytokinetcis media release, results will be presented as a poster at the 2009 American Society of Hematology Annual Meeting.